MET and non-small cell lung carcinoma: MET exon 14 skipping mutations and MET amplifications [41] predict response to targeted treatment with MET inhibitors, such as crizotinib [42], capmatinib [43,44], both FDA approved for NSCLC harboring MET exon 14 skipping mutations [45], or tepotinib [46,47].